VRTX vs REGN — Key Metrics

Metric VRTX (VERTEX PHARMACEUTICALS INC) REGN (REGENERON PHARMACEUTICALS INC)
Price536.45945.53
Market Cap136.01 Billion97.81 Billion
P/E (TTM)34.2320.11
P/B (Quarterly)6.4362.865
P/S (TTM)10.55.79
Net Profit Margin (TTM)30.728.5
Gross Margin (TTM)85.585.8
ROE (TTM)20.115.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

VERTEX PHARMACEUTICALS INC
vs
 
REGENERON PHARMACEUTICALS INC
 
VERTEX PHARMACEUTICALS INC
vs
 
REGENERON PHARMACEUTICALS INC
Performance Comparison
AI Model Recommendation
VRTX · VERTEX PHARMACEUTICALS INC

Outperform

42
UnderperformOutperform
REGN · REGENERON PHARMACEUTICALS INC

Outperform

60
UnderperformOutperform
Recommendation Summary

Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: REGN.

Financial Metrics
Prices delayed ~15 min
VRTX Metrics REGN
$536.45 Price $945.53
— Market Capitalization —
34.23 Price to Earnings Ratio 20.11
10.5 Price to Sales 5.79
42.47 Price to FCF Ratio 25.56
12.28 Price to Gross Profit 6.75
32.0 Price to R&D 14.83
11.64 Price to Current Assets 4.7

VRTX vs REGN at a glance

Vertex Pharmaceuticals INC (VRTX) and Regeneron Pharmaceuticals INC (REGN) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $97.8 billion for REGN, about 1.4 times the size.

On trailing-twelve-month figures, VRTX trades at 34.2 times trailing earnings and REGN at 20.1; net profit margins are 30.7% and 28.5%.

The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.